69190-56-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-3-chlorotoluene serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a building block in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-3-chlorotoluene is utilized as an intermediate for the production of pesticides and other agrochemicals. Its properties make it suitable for the creation of compounds that can protect crops and enhance agricultural productivity.
Used in Dye and Pigment Production:
2-Bromo-3-chlorotoluene is also employed as a chemical intermediate in the manufacturing of dyes and pigments. Its halogenated nature plays a role in the color intensity and stability of these products, which are used in a wide range of applications from textiles to printing inks.
Used in Organic Compound Synthesis:
Beyond its applications in specific industries, 2-Bromo-3-chlorotoluene is a versatile intermediate for the synthesis of other organic compounds. Its reactivity and structural features make it a valuable component in organic chemistry for creating a diverse array of specialty chemicals.

InChI:InChI=1/C7H6BrCl/c1-5-3-2-4-6(9)7(5)8/h2-4H,1H3

Upstream product

• 87-63-8 2-chloro-6-methylaniline 
• 570-24-1 2-Methyl-6-nitroaniline 

Downstream Products

• 134271-35-5 bis(2-chloro-6-methylphenyl)methanol 
• 116529-64-7 2-bromo-3-chlorobenzoyl chloride 
• 56961-26-3 2-bromo-3-chlorobenzoic acid 
• 87-63-8 2-chloro-6-methylaniline 
• 1021089-12-2 2-bromo-3-chlorophenylacetic acid methyl ester 
• 220453-60-1 2-bromo-3-chlorobenzyl bromide 

Relevant academic research and scientific papers

Theramutein modulators

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

THERAMUTEIN MODULATORS

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

Synthesis of 9,10-dihydrosilaanthracenes with substituents ortho to the silicon and methylene bridges

The generation of 9,10-dihydrosilaanthracenes with substituents on benzo ring carbons, specifically in the 4,5-positions adjacent to the methylene bridge, has been developed.Attempts to prepare the 1,8-isomer where the substituents are adjacent to the silicon bridge are also described.The diarylmethane precursors to the substituted 9,10-dihydrosilaanthracenes required the synthesis of 2,3-dihalotoluenes as well as isomeric 2,6-disubstituted benzaldehydes which were then condensed to diarylmethanols through the Grignard reagents.Ring closure to the 4,5-dimethyl-9,9-dialkyl-9,10-dihydro-9-silaanthracene, I, required the use of Rieke magnesium.The structure of I (alkyl = iPr) was determined and demonstrates that the introduction of substituents adjacent to the methylene bridge causes the dihydrosilaanthracene framework to become nearly planar with a dihedral (or butterfly) angle of 170 deg C.

Substituted 9,10-dihydroanthracen-9,10-imines

Substituted 9,10-dihydroanthracen-9,10-imines are disclosed to be minor tranquilizers, anticonvulsnts, muscle relaxants, and to be useful in the treatment of extrapyramidal disorders such as Parkinson's disease; also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions.

7 AND 8-Halo substituted 1,2,3,4-tetrahydroisoquinoline compounds

1,2,3,4-Tetrahydroisoquinoline compounds having 7 and 8 halo substituents are inhibitors of phenylethanolamine N-methyltransferase.

Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase

Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using 7 and/or 8 substituted 1,2,3,4-tetrahydroisoquinoline compounds.